Financial Information :: Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

Learn More

Latest Financial Results

Q3 2025

Quarter Ended Sep 30, 2025

Earnings Release

Earnings Webcast

Audio

10-Q

PDF HTML

XBRL

ZIP

Latest 10-K

View HTML View PDF